CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

It's frustrating, but you're not alone! As we get older, our bodies don't respond the same way to weight loss efforts, and science has some explanations to offer. As we age we naturally tend to ...

Metsera has shared positive topline results from the Phase 2a trial, reporting up to 11.3% mean placebo-adjusted weight loss at 12 weeks, with no evidence of a plateau. These results demonstrate the ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...